Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.

abstract：:Anticancer peptide (ACP) is a kind of small peptides that can kill cancer cells without damaging normal cells. In recent years, ACP has been pre-clinically used for cancer treatment. Therefore, accurate identification of ACPs will promote their clinical applications. In contrast to labor-intensive experimental techniq...

journal_title：Current drug targets

authors： Feng P,Wang Z

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND:The intracellular multiprotein complex termed the inflammasome functions as a platform of pro-inflammatory cytokine production such as IL-1β and IL-18. Under certain conditions, however, the inflammasome produces non-canonical effects such as induction of cell death, pyroptosis and cell metabolism alteration...

journal_title：Current drug targets

authors： Conley SM,Abais JM,Boini KM,Li PL

更新日期：2017-01-01 00:00:00

abstract：:RNA, as an intermediate in the production of every gene encoded protein and the genetic material of many pathogenic viruses, presents an attractive target for both biological and therapeutic manipulation. Despite its extensive involvement in living systems, its chemical diversity based on four units is relatively low ...

journal_title：Current drug targets

authors： Cairns MJ,Saravolac EG,Sun LQ

更新日期：2002-06-01 00:00:00

abstract：:Molecularly targeting signaling pathways that are involved in the pathogenesis of hematopoietic malignancies may lead to more specific and efficacious therapies. Activation of the RAS signal transduction cascade is a common feature in the molecular pathogenesis of hematologic malignancies. A number of novel agents tar...

journal_title：Current drug targets

authors： Morgan MA,Ganser A,Reuter CW

更新日期：2007-02-01 00:00:00

abstract：:Breast cancer remains the leading cause of cancer death among females worldwide. It signifies a shift from the previous decade during which the most common cause of cancer death was cervical cancer. Current treatment modalities, including surgery, radiotherapy, and adjuvant chemotherapy or hormone therapy, have not be...

journal_title：Current drug targets

authors： Sinha D,Biswas J,Sung B,Aggarwal BB,Bishayee A

更新日期：2012-12-01 00:00:00

abstract：:The emergency of responsive drug delivery systems has contributed to the reduced cytotoxicity, the improved permeability in tissues and extended circulation time of the active drug. Of particular, enzyme-responsive nanoplatforms have attracted a lot due to the specificity and efficiency of an enzyme-catalyzed reaction...

journal_title：Current drug targets

authors： Lou XF,Du YZ,Xu XL

更新日期：2021-01-13 00:00:00

abstract：:The etiopathogenesis of Crohn's disease (CD) and ulcerative Colitis (UC), the two major forms of inflammatory bowel disease (IBD), is still unknown. Although the exact cause and mechanisms of both IBD have yet to be completely understood, it is widely accepted that both CD and UC result from an inappropriate immune re...

journal_title：Current drug targets

authors： Stefanelli T,Malesci A,Repici A,Vetrano S,Danese S

更新日期：2008-05-01 00:00:00

abstract：:Cancer cells produce high levels of reactive oxygen species (ROS) that lead to a state of increased basal oxidative stress. Since this state of oxidative stress makes cancer cells vulnerable to agents that further augment ROS levels, the use of pro-oxidant agents is emerging as an exciting strategy to selectively targ...

journal_title：Current drug targets

authors： Martin-Cordero C,Leon-Gonzalez AJ,Calderon-Montano JM,Burgos-Moron E,Lopez-Lazaro M

更新日期：2012-07-01 00:00:00

abstract：:Enzymes are proteins that act as biological catalysts to speed up cellular biochemical processes. According to their main Enzyme Commission (EC) numbers, enzymes are divided into six categories: EC-1: oxidoreductase; EC-2: transferase; EC-3: hydrolase; EC-4: lyase; EC-5: isomerase and EC-6: synthetase. Different enzym...

journal_title：Current drug targets

authors： Tan JX,Lv H,Wang F,Dao FY,Chen W,Ding H

更新日期：2019-01-01 00:00:00

abstract：:The CD6 molecule is a pan T cell marker involved in T cell regulation. Although CD6 expression has been correlated with human autoimmune diseases, only a few therapeutic approaches are exploring this molecule as target in the clinic. The biological functions and mechanisms of actions of CD6 have not been definitively ...

journal_title：Current drug targets

authors： Hernández P,Moreno E,Aira LE,Rodríguez PC

更新日期：2016-01-01 00:00:00

abstract：:Inflammatory bowel disease diagnostic and management algorithms continue to rapidly evolve. This is partly driven by advanced radiologic techniques that provide objective, non-invasive evaluations. The realms of information provided by radiology and endoscopy continue to be intertwined. This has led to the question of...

journal_title：Current drug targets

authors： Bruining DH

更新日期：2012-09-01 00:00:00

abstract：:The development of databases devoted to biological information opened the possibility to integrate, query and analyze biological data obtained from several sources that otherwise would be scattered through the web. Several issues arise in the handling of biological information, mainly due to the diversity of biologica...

journal_title：Current drug targets

authors： Timmers LF,Pauli I,Barcellos GB,Rocha KB,Caceres RA,de Azevedo WF Jr,Soares MB

更新日期：2009-03-01 00:00:00

abstract：:Baculoviruses have adapted novel tactics to transcribe their genes during the late stages of replication. These include a DNA-directed RNA polymerase which is evolutionarily divergent from cellular polymerases. The viral RNA polymerase is a multisubunit and multifunctional RNA polymerase that has the ability to recogn...

journal_title：Current drug targets

authors： Passarelli AL,Guarino LA

更新日期：2007-10-01 00:00:00

abstract：:Parkinson's disease (PD) is characterized by relatively selective degeneration of dopaminergic neurons in the substantia nigra and loss of dopamine in the striatum. More than 50 epidemiological studies confirmed the low incidence of PD in smokers. Examining the distribution of subtypes of nicotinic acetylcholine recep...

journal_title：Current drug targets

authors： Kawamata J,Suzuki S,Shimohama S

更新日期：2012-05-01 00:00:00

abstract：:Tachykinins (TKs) and their receptors (NK1, NK2 and NK3), which are diffusely expressed in the human gastrointestinal tract, represent an endogenous modulator system regulating enteric secretomotor functions, inflammatory and immune responses, and visceral hypersensitivity, mainly during pathological gut diseases. Pat...

journal_title：Current drug targets

authors： Improta G,Broccardo M

更新日期：2006-08-01 00:00:00

abstract：:The Metabolic Syndrome is a common metabolic disease associated with an increased risk for atherosclerotic cardiovascular disease and mortality. In contrast to "traditional" risk factors for atherosclerosis, such as low-density lipoprotein cholesterol, the Metabolic Syndrome represents a network of interacting risk fa...

journal_title：Current drug targets

authors： Péterfy M,Davis RC,Lusis AJ

更新日期：2007-11-01 00:00:00

abstract：:Recently, the presence of functional interaction between the opioid and cannabinoid system has been shown in various pharmacological responses. Although there is an increasing interest for the feasible therapeutic application of a co-administration of cannabinoids and opioids in some disorders (i.e. to manage pain, to...

journal_title：Current drug targets

authors： Parolaro D,Rubino T,Viganò D,Massi P,Guidali C,Realini N

更新日期：2010-04-01 00:00:00

abstract：:Autophagy is a process the primary role of which is to clear up damaged cellular components such as long-lived proteins and organelles, thus participating in the conservation of different cells. Osteoporosis associated with aging is characterized by consistent changes in bone metabolism with suppression of bone format...

journal_title：Current drug targets

authors： Wang T,He H,Liu S,Jia C,Fan Z,Zhong C,Yu J,Liu H,He C

更新日期：2019-01-01 00:00:00

abstract：:It is well documented that elevated levels of PAI-1 in plasma can decrease the fibrinolytic activity in blood with an associated increased risk of thrombus formation. A diverse range of molecules including bacterial lipopolysaccharide (LPS), the inflammatory mediators tumor necrosis factor alpha (TNFalpha) and interle...

journal_title：Current drug targets

authors： Balsara RD,Xu Z,Ploplis VA

更新日期：2007-09-01 00:00:00

abstract：:Prostaglandins serve as the connecting link between inflammation and cancer. mPGES1, the downstream enzyme in the prostaglandin pathway is considered a better target than COX-2 against the progression of cancer due to the cardiovascular and other complications associated with the inhibition of the latter. Despite the ...

journal_title：Current drug targets

authors： Ramanan M,Doble M

更新日期：2017-01-01 00:00:00

abstract：:Immunity is a balanced status with adequate biological defenses to recognize and fight "non-self", as well as adequate tolerance to recognize "self". To maintain this immune homeostasis, a well-organized T cell immune network is required, which in part depends on the well-controlled development of alternative effector...

journal_title：Current drug targets

authors： Liu HX,Jiang A,Chen T,Qu W,Yan HY,Ping J

更新日期：2017-01-01 00:00:00

abstract：:The production of reactive oxygen species is a normal part of cell physiology, but many internal and external stimuli are able to trigger the production of excess levels of oxidants that are potentially damaging. The threat of oxidative damage is particularly significant to DNA, as damaged bases can interfere with rep...

journal_title：Current drug targets

authors： Shaukat Z,Liu D,Hussain R,Khan M,Gregory SL

更新日期：2016-01-01 00:00:00

abstract：:Treatment of chronic myeloid leukemia (CML) with interferon-alpha (IFN-α) was introduced in the early 1980s. Several clinical trials showed a survival advantage for patients treated with IFN-α compared to conventional chemotherapy. Some patients achieved longstanding complete cytogenetic remissions (i.e. >2 log tumor ...

journal_title：Current drug targets

authors： Simonsson B,Hjorth-Hansen H,Bjerrum OW,Porkka K

更新日期：2011-03-01 00:00:00

abstract：:Cyclooxygenase-2 (Cox-2) is an inducible enzyme involved in the conversion of arachidonic acid to prostaglandin and other eicosanoids. Molecular pathology studies have revealed that Cox-2 is over-expressed in cancer and stroma cells during tumor progression, and anti-cancer chemo-radiotherapies induce expression of Co...

journal_title：Current drug targets

authors： Khan Z,Khan N,Tiwari RP,Sah NK,Prasad GB,Bisen PS

更新日期：2011-06-01 00:00:00

abstract：:Atherosclerosis is now widely appreciated to represent a chronic inflammatory reaction of the vascular wall in response to dyslipidemia and endothelial distress involving the inflammatory recruitment of leukocytes and the activation of resident vascular cells. The proliferative response of smooth muscle cells critical...

journal_title：Current drug targets

authors： Weber C,Schober A,Zernecke A

更新日期：2010-08-01 00:00:00

abstract：:Over the past years, there was an explosion in the knowledge of the protein target and molecular mechanism associated with various disease types and in the new research of drugs of natural origin. The key idea is to evaluate bioactive natural products interacting with protein domains of different genetic origin but st...

journal_title：Current drug targets

authors： Braca A,Dal Piaz F,Marzocco S,Autore G,Vassallo A,De Tommasi N

更新日期：2011-03-01 00:00:00

abstract：:Epigenetic modifications ensure the maintenance of normal cellular functions, and their dysregulation is frequently found in many disease states, including cancer. Nowadays, the most studied epigenetic dysregulation associated with tumorigenesis, cancer progression and metastasis refers to the variations in DNA methyl...

journal_title：Current drug targets

authors： Lin SQ,Li X

更新日期：2020-01-01 00:00:00

abstract：:Type 2 diabetes, which has dramatically increased during the last decade normally results from a combination of pancreatic beta cell dysfunction and insulin resistance. One of the most recent risk factors identified for type 2 diabetes is a sub-optimal fetal and neonatal environment. Numerous human epidemiological stu...

journal_title：Current drug targets

authors： Reusens B,Ozanne SE,Remacle C

更新日期：2007-08-01 00:00:00

abstract：BACKGROUND:Nanotechnology deals with the manufacturing of materials at the atomic and molecular scale. According to the National Nanotechnology Initiative, nanotechnology denotes those structures which are nearly in 1-100 nm size regime in at least one dimension. OBJECTIVE:Nanotechnology in drug delivery has been evid...

journal_title：Current drug targets

authors： Jain A,Kumari R,Tiwari A,Verma A,Tripathi A,Shrivastava A,Jain SK

更新日期：2018-01-01 00:00:00

abstract：:Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a natural protein expressed in a wide range of tissues in our body. It is a promising anti-cancer agent due to its selective killing of cancer cells, rendering normal cells unharmed. However, resistance occurs either intrinsically or develops ove...

journal_title：Current drug targets

authors： Ngai SC

更新日期：2020-01-01 00:00:00